{"id":62071,"date":"2026-05-08T09:21:12","date_gmt":"2026-05-08T09:21:12","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/62071\/"},"modified":"2026-05-08T09:21:12","modified_gmt":"2026-05-08T09:21:12","slug":"roche-acquires-pathai-to-enhance-ai-based-diagnostic-solutions-for-cancer-detection-etenterpriseai","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/62071\/","title":{"rendered":"Roche Acquires PathAI to Enhance AI-based Diagnostic Solutions for Cancer Detection, ETEnterpriseai"},"content":{"rendered":"<p>                                        <img fetchpriority=\"high\" decoding=\"async\" width=\"590\" height=\"442\" class=\"unveil\" loading=\"eager\" style=\"width:100%;max-height:100%\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/05\/130953213.cms.png\" captionrendered=\"1\" alt=\"&lt;p&gt;Swiss pharmaceutical giant Roche announced on Thursday an agreement to acquire US firm PathAI, which specialises in digital imaging and artificial intelligence-based solutions.&lt;\/p&gt;\"\/>Swiss pharmaceutical giant Roche announced on Thursday an agreement to acquire US firm PathAI, which specialises in digital imaging and artificial intelligence-based solutions.<br \/>Swiss pharmaceutical giant Roche announced on Thursday an agreement to acquire US firm <a id=\"35979547\" type=\"General\" weightage=\"20\" keywordseo=\"PathAI\" source=\"keywords\" meta.keywordsubtype=\"org\" meta.entityname=\"PathAI\" meta.hostid=\"450\" class=\"news-keywords\" href=\"https:\/\/enterpriseai.economictimes.indiatimes.com\/tag\/pathai\" rel=\"nofollow noopener\" target=\"_blank\">PathAI<\/a>, which specialises in digital imaging and artificial intelligence-based solutions.<\/p>\n<p>As part of a drive to strengthen analytical tools within its diagnostics business the Swiss group said it has agreed to pay $750 million (637 million euros) to acquire <a href=\"https:\/\/enterpriseai.economictimes.indiatimes.com\/tag\/pathai\" rel=\"nofollow noopener\" target=\"_blank\">PathAI<\/a>, a company it has been collaborating with since 2021.<\/p>\n<p>The deal includes up to an extra $300 million in milestone payments, Roche stated.<\/p>\n<p>The accord, which remains subject to regulatory approval, is expected to be finalised in the second half of this year.<\/p>\n<p>Roche was already working with Boston-based PathAI within a partnership launched five years ago and then strengthened in 2024 to develop AI-powered algorithms for diagnostics.<\/p>\n<p>The acquisition will enable Roche to strengthen its position in <a id=\"22603173\" type=\"General\" weightage=\"20\" keywordseo=\"digital-pathology\" source=\"keywords\" class=\"news-keywords\" href=\"https:\/\/enterpriseai.economictimes.indiatimes.com\/tag\/digital+pathology\" rel=\"nofollow noopener\" target=\"_blank\">digital pathology<\/a>, designed to transform workflows notably by enabling the creation of high-resolution images of tissue and improving diagnosis accuracy, particularly for cancers, said Roche.<\/p>\n<p>In a market note Urban Fritsche, analyst with the Zurich Kantonalbank, saw the deal as &#8220;a smaller acquisition that will not impact sales in the short term, but whose platform is certain to become an important tool for new and further developments.&#8221;<\/p>\n<p>Roche shares were up around 0.6 percent in mid-morning Thursday at 324 francs.\n                                                                    <\/p>\n<p>                                    Published On May 8, 2026 at 12:30 PM IST<\/p>\n<p>\n                Join the community of 2M+ industry professionals.<br \/>\n                Subscribe to Newsletter to get latest insights &amp; analysis in your inbox.\n            <\/p>\n<p>            Get updates on your preferred social platform<br \/>\n            Follow us for the latest news, insider access to events and more.<\/p>\n","protected":false},"excerpt":{"rendered":"Swiss pharmaceutical giant Roche announced on Thursday an agreement to acquire US firm PathAI, which specialises in digital&hellip;\n","protected":false},"author":2,"featured_media":62072,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[34148,34149,7095,34150,33848,134,27592],"class_list":{"0":"post-62071","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-ai-driven-diagnostics","9":"tag-artificial-intelligence-in-healthcare","10":"tag-digital-pathology","11":"tag-makingaiwork","12":"tag-pathai","13":"tag-roche","14":"tag-roche-acquisition"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116538224615262421","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/62071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=62071"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/62071\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/62072"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=62071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=62071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=62071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}